Variability of spirometry in chronic obstructive pulmonary disease

Results from two clinical trials

Laura B. Herpel, Richard E. Kanner, Shing M. Lee, Henry E. Fessler, Frank C. Sciurba, John E Connett, Robert A. Wise

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Objective: Our goal is to determine short-term intraindividual biologic and measurement variability in spirometry of patients with a wide range of stable chronic obstructive pulmonary disease severity, using datasets fromthe National Emphysema Treatment Trial (NETT) and the Lung Health Study (LHS). This may be applied to determine criteria that can be used to assess a clinically meaningful change in spirometry. Methods: A total of 5,886 participants from the LHS and 1,215 participants from the NETT performed prebronchodilator spirometry during two baseline sessions. We analyzed varying criteria for absolute and percent change of FEV1 and FVC to determine which criterion was met by 90% of the participants. Results: The mean ± SD FEV1 for the initial session was 2.64 ± 0.60 L (75.1 ± 8.8% predicted) for the LHS and 0.68 ± 0.22 L (23.7 ± 6.5% predicted) for the NETT. The mean ± SD number of days between test sessions was 24.9 ± 17.1 for the LHS and 85.7 ± 21.7 for the NETT. As the degree of obstruction increased, the intersession percent difference of FEV1 increased. However, the absolute difference between tests remained relatively constant despite the severity of obstruction (0.106 ± 0.10 L). Over 90% of participants had an intersession FEV1 difference of less than 225 ml irrespective of the severity of obstruction. Conclusions: Absolute changes in FEV1 rather than percent change should be used to determine whether patients with chronic obstructive pulmonary disease have improved or worsened between test sessions.

Original languageEnglish (US)
Pages (from-to)1106-1113
Number of pages8
JournalAmerican journal of respiratory and critical care medicine
Volume173
Issue number10
DOIs
StatePublished - May 15 2006

Fingerprint

Spirometry
Emphysema
Chronic Obstructive Pulmonary Disease
Clinical Trials
Lung
Health
Therapeutics

Keywords

  • Forced expiratory volume
  • Obstructive lung diseases
  • Reproducibility of measurements
  • Spirometry
  • Vital capacity

Cite this

Variability of spirometry in chronic obstructive pulmonary disease : Results from two clinical trials. / Herpel, Laura B.; Kanner, Richard E.; Lee, Shing M.; Fessler, Henry E.; Sciurba, Frank C.; Connett, John E; Wise, Robert A.

In: American journal of respiratory and critical care medicine, Vol. 173, No. 10, 15.05.2006, p. 1106-1113.

Research output: Contribution to journalArticle

Herpel, Laura B. ; Kanner, Richard E. ; Lee, Shing M. ; Fessler, Henry E. ; Sciurba, Frank C. ; Connett, John E ; Wise, Robert A. / Variability of spirometry in chronic obstructive pulmonary disease : Results from two clinical trials. In: American journal of respiratory and critical care medicine. 2006 ; Vol. 173, No. 10. pp. 1106-1113.
@article{31e4b9fa3ed34120ad563a96e2b90b8b,
title = "Variability of spirometry in chronic obstructive pulmonary disease: Results from two clinical trials",
abstract = "Objective: Our goal is to determine short-term intraindividual biologic and measurement variability in spirometry of patients with a wide range of stable chronic obstructive pulmonary disease severity, using datasets fromthe National Emphysema Treatment Trial (NETT) and the Lung Health Study (LHS). This may be applied to determine criteria that can be used to assess a clinically meaningful change in spirometry. Methods: A total of 5,886 participants from the LHS and 1,215 participants from the NETT performed prebronchodilator spirometry during two baseline sessions. We analyzed varying criteria for absolute and percent change of FEV1 and FVC to determine which criterion was met by 90{\%} of the participants. Results: The mean ± SD FEV1 for the initial session was 2.64 ± 0.60 L (75.1 ± 8.8{\%} predicted) for the LHS and 0.68 ± 0.22 L (23.7 ± 6.5{\%} predicted) for the NETT. The mean ± SD number of days between test sessions was 24.9 ± 17.1 for the LHS and 85.7 ± 21.7 for the NETT. As the degree of obstruction increased, the intersession percent difference of FEV1 increased. However, the absolute difference between tests remained relatively constant despite the severity of obstruction (0.106 ± 0.10 L). Over 90{\%} of participants had an intersession FEV1 difference of less than 225 ml irrespective of the severity of obstruction. Conclusions: Absolute changes in FEV1 rather than percent change should be used to determine whether patients with chronic obstructive pulmonary disease have improved or worsened between test sessions.",
keywords = "Forced expiratory volume, Obstructive lung diseases, Reproducibility of measurements, Spirometry, Vital capacity",
author = "Herpel, {Laura B.} and Kanner, {Richard E.} and Lee, {Shing M.} and Fessler, {Henry E.} and Sciurba, {Frank C.} and Connett, {John E} and Wise, {Robert A.}",
year = "2006",
month = "5",
day = "15",
doi = "10.1164/rccm.200506-975OC",
language = "English (US)",
volume = "173",
pages = "1106--1113",
journal = "American Journal of Respiratory and Critical Care Medicine",
issn = "1073-449X",
publisher = "American Thoracic Society",
number = "10",

}

TY - JOUR

T1 - Variability of spirometry in chronic obstructive pulmonary disease

T2 - Results from two clinical trials

AU - Herpel, Laura B.

AU - Kanner, Richard E.

AU - Lee, Shing M.

AU - Fessler, Henry E.

AU - Sciurba, Frank C.

AU - Connett, John E

AU - Wise, Robert A.

PY - 2006/5/15

Y1 - 2006/5/15

N2 - Objective: Our goal is to determine short-term intraindividual biologic and measurement variability in spirometry of patients with a wide range of stable chronic obstructive pulmonary disease severity, using datasets fromthe National Emphysema Treatment Trial (NETT) and the Lung Health Study (LHS). This may be applied to determine criteria that can be used to assess a clinically meaningful change in spirometry. Methods: A total of 5,886 participants from the LHS and 1,215 participants from the NETT performed prebronchodilator spirometry during two baseline sessions. We analyzed varying criteria for absolute and percent change of FEV1 and FVC to determine which criterion was met by 90% of the participants. Results: The mean ± SD FEV1 for the initial session was 2.64 ± 0.60 L (75.1 ± 8.8% predicted) for the LHS and 0.68 ± 0.22 L (23.7 ± 6.5% predicted) for the NETT. The mean ± SD number of days between test sessions was 24.9 ± 17.1 for the LHS and 85.7 ± 21.7 for the NETT. As the degree of obstruction increased, the intersession percent difference of FEV1 increased. However, the absolute difference between tests remained relatively constant despite the severity of obstruction (0.106 ± 0.10 L). Over 90% of participants had an intersession FEV1 difference of less than 225 ml irrespective of the severity of obstruction. Conclusions: Absolute changes in FEV1 rather than percent change should be used to determine whether patients with chronic obstructive pulmonary disease have improved or worsened between test sessions.

AB - Objective: Our goal is to determine short-term intraindividual biologic and measurement variability in spirometry of patients with a wide range of stable chronic obstructive pulmonary disease severity, using datasets fromthe National Emphysema Treatment Trial (NETT) and the Lung Health Study (LHS). This may be applied to determine criteria that can be used to assess a clinically meaningful change in spirometry. Methods: A total of 5,886 participants from the LHS and 1,215 participants from the NETT performed prebronchodilator spirometry during two baseline sessions. We analyzed varying criteria for absolute and percent change of FEV1 and FVC to determine which criterion was met by 90% of the participants. Results: The mean ± SD FEV1 for the initial session was 2.64 ± 0.60 L (75.1 ± 8.8% predicted) for the LHS and 0.68 ± 0.22 L (23.7 ± 6.5% predicted) for the NETT. The mean ± SD number of days between test sessions was 24.9 ± 17.1 for the LHS and 85.7 ± 21.7 for the NETT. As the degree of obstruction increased, the intersession percent difference of FEV1 increased. However, the absolute difference between tests remained relatively constant despite the severity of obstruction (0.106 ± 0.10 L). Over 90% of participants had an intersession FEV1 difference of less than 225 ml irrespective of the severity of obstruction. Conclusions: Absolute changes in FEV1 rather than percent change should be used to determine whether patients with chronic obstructive pulmonary disease have improved or worsened between test sessions.

KW - Forced expiratory volume

KW - Obstructive lung diseases

KW - Reproducibility of measurements

KW - Spirometry

KW - Vital capacity

UR - http://www.scopus.com/inward/record.url?scp=33646552080&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33646552080&partnerID=8YFLogxK

U2 - 10.1164/rccm.200506-975OC

DO - 10.1164/rccm.200506-975OC

M3 - Article

VL - 173

SP - 1106

EP - 1113

JO - American Journal of Respiratory and Critical Care Medicine

JF - American Journal of Respiratory and Critical Care Medicine

SN - 1073-449X

IS - 10

ER -